158 related articles for article (PubMed ID: 21298495)
1. Familial diabetes is associated with reduced risk of cancer in diabetic patients: a possible role for metformin.
Berstein LM; Boyarkina MP; Teslenko SY
Med Oncol; 2012 Jun; 29(2):1308-13. PubMed ID: 21298495
[TBL] [Abstract][Full Text] [Related]
2. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.
Donadon V; Balbi M; Casarin P; Vario A; Alberti A
World J Gastroenterol; 2008 Oct; 14(37):5695-700. PubMed ID: 18837086
[TBL] [Abstract][Full Text] [Related]
3. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
[TBL] [Abstract][Full Text] [Related]
4. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Blonde L; Klein EJ; Han J; Zhang B; Mac SM; Poon TH; Taylor KL; Trautmann ME; Kim DD; Kendall DM
Diabetes Obes Metab; 2006 Jul; 8(4):436-47. PubMed ID: 16776751
[TBL] [Abstract][Full Text] [Related]
5. Metformin and cancer: new applications for an old drug.
Kourelis TV; Siegel RD
Med Oncol; 2012 Jun; 29(2):1314-27. PubMed ID: 21301998
[TBL] [Abstract][Full Text] [Related]
6. Metformin use associated with lower risk of cancer in patients with diabetes mellitus type 2.
Kusturica J; Kulo Ćesić A; Gušić E; Maleškić S; Rakanović-Todić M; Šečić D
Med Glas (Zenica); 2017 Aug; 14(2):176-181. PubMed ID: 28698536
[TBL] [Abstract][Full Text] [Related]
7. An economic evaluation of colesevelam when added to metformin-, insulin- or sulfonylurea-based therapies in patients with uncontrolled type 2 diabetes mellitus.
Simons WR; Hagan MA
Pharmacoeconomics; 2010; 28(9):765-80. PubMed ID: 20799756
[TBL] [Abstract][Full Text] [Related]
8. Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes - a simulation with the Diabetes Mellitus Model (DMM).
Janka HU; Hessel F; Walzer S; Mã Ller E
Int J Clin Pharmacol Ther; 2007 Dec; 45(12):623-30. PubMed ID: 18184530
[TBL] [Abstract][Full Text] [Related]
9. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus.
Tseng CH
Diabetes Metab Res Rev; 2015 Sep; 31(6):619-26. PubMed ID: 25820555
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer.
Berstein LM; Iyevleva AG; Vasilyev D; Poroshina TE; Imyanitov EN
Cell Cycle; 2013 Dec; 12(23):3681-8. PubMed ID: 24145224
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.
Kiayias JA; Vlachou ED; Theodosopoulou E; Lakka-Papadodima E
Diabetes Care; 2002 Jul; 25(7):1251-2. PubMed ID: 12087036
[No Abstract] [Full Text] [Related]
12. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
Turner RC; Cull CA; Frighi V; Holman RR
JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
[TBL] [Abstract][Full Text] [Related]
13. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.
Donadon V; Balbi M; Mas MD; Casarin P; Zanette G
Liver Int; 2010 May; 30(5):750-8. PubMed ID: 20331505
[TBL] [Abstract][Full Text] [Related]
14. 10-year follow-up of intensive glucose control in type 2 diabetes.
Holman RR; Paul SK; Bethel MA; Matthews DR; Neil HA
N Engl J Med; 2008 Oct; 359(15):1577-89. PubMed ID: 18784090
[TBL] [Abstract][Full Text] [Related]
15. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy.
Riedel AA; Heien H; Wogen J; Plauschinat CA
Pharmacotherapy; 2007 Aug; 27(8):1102-10. PubMed ID: 17655510
[TBL] [Abstract][Full Text] [Related]
16. Patterns and determinants of new first-line antihyperglycaemic drug use in patients with type 2 diabetes mellitus.
Geier AS; Wellmann I; Wellmann J; Kajüter H; Heidinger O; Hempel G; Hense HW
Diabetes Res Clin Pract; 2014 Oct; 106(1):73-80. PubMed ID: 25139631
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of the effects of steroid therapy and antidiabetic medication on survival in diabetic glioblastoma patients.
Welch MR; Grommes C
CNS Oncol; 2013 May; 2(3):237-46. PubMed ID: 25054464
[TBL] [Abstract][Full Text] [Related]
18. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
19. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients.
Monami M; Colombi C; Balzi D; Dicembrini I; Giannini S; Melani C; Vitale V; Romano D; Barchielli A; Marchionni N; Rotella CM; Mannucci E
Diabetes Care; 2011 Jan; 34(1):129-31. PubMed ID: 20980415
[TBL] [Abstract][Full Text] [Related]
20. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
Hershon KS; Hershon PM
Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]